PHARMAUST LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.24 AUD | -4.00% |
|
-15.79% | +108.70% |
| Apr. 23 | Pharmaust CEO Resigns | MT |
| Apr. 10 | PharmAust Obtains Approval to Commence Monepantel Extension Study | MT |
Valuation
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8.158 | 10.65 | 46.81 | 28.82 | 22.18 | 26.06 |
| Enterprise Value (EV) 1 | 6.702 | 8.878 | 45.4 | 27.08 | 21.15 | 24.39 |
| P/E ratio | -2.38 x | -5.37 x | -33.7 x | -21.5 x | -13 x | -3.88 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.5 x | 2.45 x | 11.4 x | 7.88 x | 4.92 x | 6.82 x |
| EV / Revenue | 2.06 x | 2.04 x | 11 x | 7.4 x | 4.69 x | 6.39 x |
| EV / EBITDA | -2.78 x | -6.58 x | -41.5 x | -24.4 x | -14.6 x | -7.91 x |
| EV / FCF | -4.53 x | -7.77 x | -50.7 x | -44 x | -27.5 x | -58 x |
| FCF Yield | -22.1% | -12.9% | -1.97% | -2.27% | -3.63% | -1.72% |
| Price to Book | 1.14 x | 1.43 x | 5.49 x | 3.25 x | 2.83 x | 6.7 x |
| Nbr of stocks (in thousands) | 198,981 | 280,221 | 302,021 | 316,730 | 316,912 | 347,475 |
| Reference price 2 | 0.0410 | 0.0380 | 0.1550 | 0.0910 | 0.0700 | 0.0750 |
| Announcement Date | 9/30/18 | 9/19/19 | 9/18/20 | 8/18/21 | 8/26/22 | 8/31/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3.259 | 4.347 | 4.12 | 3.657 | 4.51 | 3.819 |
| EBITDA 1 | -2.412 | -1.349 | -1.094 | -1.109 | -1.453 | -3.081 |
| EBIT 1 | -2.53 | -1.521 | -1.247 | -1.273 | -1.62 | -3.254 |
| Operating Margin | -77.64% | -35% | -30.26% | -34.81% | -35.92% | -85.19% |
| Earnings before Tax (EBT) 1 | -2.522 | -1.551 | -1.362 | -1.337 | -1.708 | -6.212 |
| Net income 1 | -2.522 | -1.551 | -1.362 | -1.337 | -1.708 | -6.212 |
| Net margin | -77.38% | -35.69% | -33.06% | -36.57% | -37.87% | -162.64% |
| EPS 2 | -0.0172 | -0.007072 | -0.004600 | -0.004235 | -0.005390 | -0.0194 |
| Free Cash Flow 1 | -1.478 | -1.143 | -0.896 | -0.6155 | -0.7686 | -0.4205 |
| FCF margin | -45.35% | -26.3% | -21.75% | -16.83% | -17.04% | -11.01% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/30/18 | 9/19/19 | 9/18/20 | 8/18/21 | 8/26/22 | 8/31/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1.46 | 1.77 | 1.41 | 1.75 | 1.03 | 1.67 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -1.48 | -1.14 | -0.9 | -0.62 | -0.77 | -0.42 |
| ROE (net income / shareholders' equity) | -35.9% | -21.3% | -17% | -15.4% | -20.4% | -106% |
| ROA (Net income/ Total Assets) | -19.1% | -11.2% | -8.06% | -7.33% | -9.63% | -25.1% |
| Assets 1 | 13.2 | 13.83 | 16.9 | 18.24 | 17.74 | 24.75 |
| Book Value Per Share 2 | 0.0400 | 0.0300 | 0.0300 | 0.0300 | 0.0200 | 0.0100 |
| Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 0.0100 |
| Capex 1 | 0.87 | 0.15 | 0.03 | 0.1 | 0.04 | 0.03 |
| Capex / Sales | 26.66% | 3.38% | 0.73% | 2.78% | 0.96% | 0.91% |
| Announcement Date | 9/30/18 | 9/19/19 | 9/18/20 | 8/18/21 | 8/26/22 | 8/31/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +108.70% | 61.83M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PAA Stock
- Financials PharmAust Limited
